Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,108 | 332 | 2,756 |
| Samples | 1,055 | 168 | 880 |
| Peptides | 751 | 115 | 672 |
Function
GRID2 · Glutamate ionotropic receptor delta type subunit 2
The protein encoded by this gene is a member of the family of ionotropic glutamate receptors which are the predominant excitatory neurotransmitter receptors in the mammalian brain. The encoded protein is a multi-pass membrane protein that is expressed selectively in cerebellar Purkinje cells. A point mutation in the mouse ortholog, associated with the phenotype named 'lurcher', in the heterozygous state leads to ataxia resulting from selective, cell-autonomous apoptosis of cerebellar Purkinje cells during postnatal development. Mice homozygous for this mutation die shortly after birth from massive loss of mid- and hindbrain neurons during late embryogenesis. This protein also plays a role in synapse organization between parallel fibers and Purkinje cells. Alternate splicing results in multiple transcript variants encoding distinct isoforms. Mutations in this gene cause cerebellar ataxia in humans. [provided by RefSeq, Apr 2014].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000282020 | O43424 | 1,166 | 722 |
| ENST00000611049 | A0A087X043* | 976 | 642 |
| ENST00000510992 | O43424-2 | 961 | 619 |
| ENST00000637838 | A0A1B0GW49* | 5 | 5 |
Gene Properties
Recurrent Mutations
All 722 amino-acid changes on canonical ENST00000282020 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRID2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRID2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Melanoma | 26/210 12% | 187/1899 10% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 12/57 21% | 52/810 6% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 76/1390 5% |
| Endometrial Carcinoma | 5/42 12% | 27/612 4% |
| Other Solid Cancers | 2/94 2% | 67/1515 4% |
| Hodgkins Lymphoma | 4/16 25% | 1/122 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 24/752 3% |
| Gastric Carcinoma | 5/74 7% | 54/1809 3% |
| Colorectal Carcinoma | 18/143 13% | 81/3239 2% |
| Head and Neck Carcinoma | 8/85 9% | 31/1574 2% |
| Bladder Carcinoma | 3/58 5% | 17/956 2% |
| Neuroendocrine Tumour | 9/154 6% | 5/577 1% |
| Other Sarcomas | 5/69 7% | 9/699 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Plasma Cell Myeloma | 0/44 0% | 5/305 2% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 31/2534 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Biliary Tract Carcinoma | 0/54 0% | 13/950 1% |
| Esophageal Carcinoma | 1/23 4% | 9/769 1% |
| Prostate Carcinoma | 4/13 31% | 22/2105 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Ovarian Carcinoma | 1/109 1% | 11/998 1% |
| Hepatocellular Carcinoma | 2/46 4% | 22/2210 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Kidney Carcinoma | 2/85 2% | 17/1862 1% |
| Glioma | 1/52 2% | 20/2127 1% |
| Breast Carcinoma | 2/144 1% | 30/3264 1% |
Mutation Distribution
Where GRID2 is mutated · all tissues, split by cell line vs tissue
How many mutations in GRID2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 49 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,108 mutations in GRID2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|